Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service ERCP & endoscopic ultrasound cases in Idaho: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (240 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 5 | 442 | 37% |
| 2020 | 6 | 456 | 40% |
| 2021 | 7 | 517 | 43% |
| 2022 | 8 | 429 | 47% |
| 2023 | 8 | 471 | 50% |
| 2024 | 12 | 559 | 52% |
| 2025 from claims | – | 659 533–774 | 54% |
| 2026 forecast | – | 780 611–979 | 49% |
| 2027 forecast | – | 846 627–1,118 | 49% |
| 2028 forecast | – | 917 649–1,266 | 49% |
| 2029 forecast | – | 995 676–1,426 | 49% |
| 2030 forecast | – | 1,079 707–1,601 | 48% |
Biliary stenting, stone extraction, EUS with FNA; the advanced-endoscopy call point. Professional codes (what the surgeon bills): CPT 43264, 43274, 43260, 43259, 43242, 43266.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 95% of the cases CMS names in Idaho; 6 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 49% inpatient hospital, 51% hospital outpatient.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 165 | 12,633+0.7%/yr | +0.7%/yr | 3.9 | 1% | 15,600 in 2030+3.6%/yr |
| Washington | 46 | 2,920−2.5%/yr | −2.5%/yr | 3.9 | 0% | 3,710 in 2030+4.1%/yr |
| Arizona | 36 | 2,770+2.8%/yr | +2.8%/yr | 3.8 | 2% | 3,300 in 2030+3%/yr |
| Colorado | 25 | 1,932+0.7%/yr | +0.7%/yr | 4.1 | 0% | 2,030 in 2030+0.9%/yr |
| Oregon | 26 | 1,050−5.1%/yr | −5.1%/yr | 2.6 | 0% | 1,370 in 2030+4.6%/yr |
| Nevada | 10 | 659−2.7%/yr | −2.7%/yr | 2.3 | 0% | 610 in 2030−1.4%/yr |
| Utah | 12 | 445−6.8%/yr | −6.8%/yr | 2.1 | 0% | 480 in 2030+1.3%/yr |
| Montana | 8 | 373−4.1%/yr | −4.1%/yr | 2.0 | 0% | 440 in 2030+2.8%/yr |
| New Mexico | 8 | 365−15%/yr | −15%/yr | 1.6 | 0% | 390 in 2030+1.1%/yr |
| Alaska | 4 | 213+6.2%/yr | +6.2%/yr | 1.8 | 0% | 220 in 2030+0.8%/yr |
| Hawaii | 5 | 193−5.6%/yr | −5.6%/yr | 1.5 | 1% | 340 in 2030+10%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Colonoscopy & upper endoscopy | 83 | 19,523−0.2%/yr | −0.2%/yr | 99.40.9× | 37% | 27,700 in 2030+6%/yr |
| Bronchoscopy & lung nodule | 5 | 286+3%/yr | +3%/yr | 1.40.6× | 0% | 650 in 2030+15%/yr |
ERCP & endoscopic ultrasound in every state, and its device makers · Every procedure market in Idaho · Every state · Compare with California
Boston Scientific leads with 41% of company spending on these surgeons in 2025, +32 pts on 2024.
In 2025, 4 companies reported engagement with Idaho’s surgeons worth $2,336 in consulting, speaking, meals and travel tied to these products, about $195 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 2 clearances and approvals in the category, 7 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.